Black Hawk Acquisition Corp (BKHA) Form 8-K — Sep 24, 2026
$BKHAForm 8-KItems 1.01, 3.02, 9.01Filed Sep 24, 2026, 4:15 PM ET0001829126-26-010385Original filing
Black Hawk Acquisition Corporation (BKHA) entered a series of financing agreements with Meteora Select Trading Opportunities Master, LP on September 22, 2026 in connection with its pending business combination with Vesicor Therapeutics, Inc. The package includes a forward purchase agreement covering up to 1,350,000 shares, a non-redemption backstop for up to 2,124,077 shares, and a subscription agreement, all funded at the SPAC's per-share redemption price.
Key figures
- Commitment fee
- 0.50% of $200.0 million
- Backstop shares
- 2,124,077 shares
- Sepa commitment
- $200.0 million
- Convert note terms
- 12-month maturity, 0% interest (18% in default), conversion at lower of fixed formula and 95% of 5-day lowest daily VWAP
- Max forward shares
- 1,350,000 shares
- Sepa advance price
- 97% of market price
- Prepaid advance oid
- 15% discount (funded at 85% of face)
- Reset price initial
- $10.00 per share
- Valuation period months
- 36 months after closing
- Expense reimbursement cap
- $75,000 aggregate
- Non redemption fee per share
- $0.75 less than redemption price
- Sepa beneficial ownership limit
- 4.9% (increasable to 9.9%)
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.